Home
Clinical Resources Search
PQI: Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

Download PQI pdf 0.12MB

Last Updated: November 29, 2023

By: Porscha Johnson, PharmD, CPGx

About this PQI

The purpose of this PQI is to review Sotorasib treatment in KRAS G12C mutated NSCLC including management of adverse effects.

More About This PQI

PQI:

Sotorasib-Lumakras®-Companion-Diagnostics-QIAGEN-therascreen®-KRAS-RGQ-PCR-Kit-and-Guardant360®-CDx_PQI_NCODA pdf 0.11MB

How to Use a Positive Quality Intervention (PQI)

Essentially, it’s a tool to improve patient care by sharing best practices in oncology care. Consider this standardized, peer-review clinical guidance to oncology healthcare teams, enabling you and your team to consistently deliver high-quality care to your patients.

Find a PQI

Find Similar Resources

All Resources

PQI PQI in Action PQI Podcast Toolkit Treatment Support Kit Video Genomics Non-Small Cell Lung Cancer (NSCLC) Guardant360 Lumakras QIAGEN Sotorasib

PQI

PQI: Ibrutinib Dosing Optimization

Author: Nick Bouchard, PharmD | Danielle Maciorowski, PharmD

Frequently Searched

Supported by

Sotorasib (Lumakras®) for KRAS G12C-mutated Non-Small Cell Lung Cancer (NSCLC)

About this PQI

More About This PQI

PQI:

How to Use a Positive Quality Intervention (PQI)

Find Similar Resources

PQI: Ibrutinib Dosing Optimization

PQI: Zanubrutinib (Brukinsa®) Patient Selection and Management

PQI: Zanubrutinib (Brukinsa ®) treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

PQI: Vorasidenib (Voranigo®)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

PQI in Action: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancerwith MET Exon 14 Alterations

PQI in Action: Siltuximab (Sylvant®) in Patients with Idiopathic Multicentric Castleman Disease

PQI in Action: Isatuximab-irfc (Sarclisa®) in 1q21 Gain or Amplifications in Relapsed/Refractory Multiple Myeloma

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings

The PQI Podcast S3 Ep 13: The Importance of the Multidisciplinary Team

Readiness Tracker

Treatment Support Kit: Abemaciclib

Treatment Support Kit: Temozolomide

Treatment Support Kit: Tivozanib

Treatment Support Kit: Regorafenib

Video: Akynzeo® (Ready-to-Use Vial): A Step-by-Step Video Guide

Video: BRUKINSA® (Zanubrutinib) for Treatment of Relapsed or Refractory Marginal Zone Lymphoma

Video: Ibrutinib-Related Cardiac Toxicities: Management & Dose Modifications

Video: Neratinib for Extended Adjuvent Treatment of Adult Patients with Early-Stage HER2-Positive Breast Cancer (MIP)

PQI: Selpercatinib (Retevmo®) Genomic Testing Management

PQI Podcast S6 Ep 2: Molecular Testing & Targeted Treatment in Colorectal Cancer

PQI Podcast S6 Ep 9: ctDNA Testing in GI Cancers

PQI Podcast S7 Ep 12: Advancing Cancer Care with Precision Medicine & the Pharmacist’s Role

PQI: Tepotinib (Tepmetko®) for Non-Small Cell Lung Cancer with MET Exon 14 Alterations

PQI: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

PQI: Selpercatinib (Retevmo®) Management

PQI: Selpercatinib (Retevmo®) Genomic Testing Management

PQI: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

PQI: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

PQI: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

PQI: Sotorasib (Lumakras®) Companion Diagnostics (QIAGEN therascreen® KRAS RGQ PCR Kit and Guardant360® CDx)

PQI in Action: Tremelimumab-actl (Imjudo®) Patient Management

The PQI Podcast S8 Ep 10: Operationalizing Bispecifics in the Community Setting

The PQI Podcast S3 Ep 11: Moffitt Clinical Pharmacy Program

The PQI Podcast S3 Ep 12: Health Disparities in Cancer Screenings